Match!
Juan Pedro-Botet
Autonomous University of Barcelona
353Publications
30H-index
4,006Citations
Publications 353
Newest
#1Juan Pedro-Botet (Autonomous University of Barcelona)H-Index: 30
#2Jose Lopez-Miranda (UCO: University of Córdoba (Spain))H-Index: 54
Last.Lluís MasanaH-Index: 37
view all 10 authors...
Pooled data from randomized clinical trials on lipid-lowering therapy have provided valuable information and clinical insights. Although cardiovascular disease is a common cause of death, mortality data have rarely been prominent in key lipid trials. The 4S, LIPID and HPS trials were the first to demonstrate a reduction in overall mortality. Lower- versus higher-intensity statin trials and non-statin lipid-lowering trials with ezetimibe and proprotein convertase subtilisin-kexin type 9 (PCSK9) i...
Source
#1Elisenda ClimentH-Index: 2
#2Albert GodayH-Index: 24
Last.David BenaigesH-Index: 18
view all 9 authors...
Source
Source
#1Elisenda Climent (Autonomous University of Barcelona)H-Index: 2
#2David Benaiges (Autonomous University of Barcelona)H-Index: 18
Last.Juan Pedro-Botet (Autonomous University of Barcelona)H-Index: 30
view all 3 authors...
Abstract Statins have been associated with an increased risk of new-onset diabetes mellitus (NODM), as confirmed in previous observational studies and meta-analyses. Controversy exists as to whether this risk varies depending on statin type or dose. However, there appears to be unanimity regarding the different associated factors that raise this risk. Furthermore, diverse pathophysiologic mechanisms have been described that could explain the increased risk of diabetes in patients with statin tre...
Source
#1Helena JuliàH-Index: 1
#2David Benaiges (Autonomous University of Barcelona)H-Index: 18
Last.Alberto GodayH-Index: 18
view all 10 authors...
Introduction Levothyroxine (LT4) requirements can presumably be modified differently after laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic sleeve gastrectomy (LSG). The present study compared changes in LT4 dose in hypothyroid subjects undergoing LRYGB or LSG 2 years after the procedure.
2 CitationsSource
#1Juan Pedro-Botet (Autonomous University of Barcelona)H-Index: 30
#2Elisenda Climent (Autonomous University of Barcelona)H-Index: 2
Last.David Benaiges (Autonomous University of Barcelona)H-Index: 18
view all 3 authors...
ABSTRACTIntroduction: Although statins have a satisfactory safety profile and are well tolerated, many statin-treated patients report muscle symptoms in clinical practice which contribute to drug d...
1 CitationsSource
#1José María Mostaza (ISCIII: Instituto de Salud Carlos III)H-Index: 23
#2Xavier Pintó (University of Barcelona)H-Index: 41
Last.Lluís VilaH-Index: 4
view all 32 authors...
Resumen La Sociedad Espanola de Arteriosclerosis tiene entre sus objetivos contribuir al mayor y mejor conocimiento de la enfermedad vascular, su prevencion y su tratamiento. Las enfermedades cardiovasculares son la primera causa de muerte en nuestro pais y conllevan ademas un elevado grado de discapacidad y de gasto sanitario. La arteriosclerosis es una enfermedad de causa multifactorial, y es por ello que su prevencion exige un abordaje global que contemple los distintos factores de riesgo con...
1 CitationsSource
#1David Benaiges (Autonomous University of Barcelona)H-Index: 18
#2Alejandra Parri (University of Barcelona)
Last.Alberto GodayH-Index: 18
view all 9 authors...
Abstract Background and objectives Bariatric surgery (BS) leads to several changes in nutritional habits that can be attributed to different mechanisms. Some of these changes could be achievable with a preoperative nutritional intervention. The objective was to evaluate dietary modifications during the preoperative and postoperative periods of BS. Methods Prospective observational study of patients who underwent BS between 2010 and 2014 at the Hospital del Mar; 60 consecutive patients were inclu...
Source
#1Lucía Gortazar (Autonomous University of Barcelona)H-Index: 2
#2Juana A. Flores Le-Roux (Autonomous University of Barcelona)H-Index: 11
Last.Alberto Goday (Autonomous University of Barcelona)H-Index: 18
view all 8 authors...
1 CitationsSource
#1Lluís MasanaH-Index: 37
#2Daiana IbarretxeH-Index: 10
Last.Xavier PintóH-Index: 41
view all 11 authors...
Abstract The introduction of singular therapies, such as proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), to lower high cholesterol levels requires better classification of patients eligible for intensive lipid lowering therapy. According to the European Medicines Administration, PCSK9i are recommended in primary prevention only in familial hypercholesterolemia (FH) patients. Therefore, an FH diagnosis is not simply an academic issue, because it has many clinical implications. ...
2 CitationsSource
12345678910